Please provide your email address to receive an email when new articles are posted on .
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Table of Contents
Key takeaways:
From the start of rehabilitation, it took a median of 1 day for patients given a mobile patient lift to stand vs. 3 days in the control group.
These patients also had better physical function at ICU discharge.
Ventilated ICU patients stood up in fewer days with a mobile patient lift plus rehabilitation protocol vs. the protocol alone, according to results published inCritical Care Medicine.
“We anticipate that proactive early mobilization, with the assistance of mobile patient lifts, will play a pivotal role in preventing post-intensive care syndrome,” Ginga Suzuki, PhD, of the Critical Care Center at Toho University Omori Medical Center in Japan, said in a press release.
Data were derived from Suzuki G, et al. Crit Care Med. 2024;doi:10.1097/CCM.0000000000006219.
In a single-center, open-label, randomized controlled trial, Suzuki and colleagues assessed 80 ICU patients expected to receive a minimum of 48 hours of mechanical ventilation to determine if mobile patient lift use promotes early mobilization.
Of the total cohort, 41 patients (median age, 69 years; 73.2% men) received a rehabilitation protocol (control group), whereas 39 patients (median age, 71 years; 46.2% men) received this protocol plus a mobile patient lift to help them with sitting, standing, transfers and walking (intervention group).
Researchers captured mobilization by comparing how long it takes each group to stand from the start of rehabilitation, and this is demonstrated through an ICU mobility scale score of 4 or higher.
Most of the patients in the intervention group used the lift (n = 34; 87.2%), according to researchers.
It only took a median of 1 day for patients receiving the intervention to stand, whereas it took a median of 3 days for control patients to stand (P < .01).
In addition to earlier mobilization, the intervention group had a higher ICU mobility scale score than the control group (6 vs. 4; P < .01) at ICU discharge, signaling more mobility.
Researchers further found significantly increased Functional Status Scores for the ICU (FSS-ICU) among those receiving the intervention vs. the control (20.4 vs. 17.9; P = .04) when assessed at ICU discharge.
In contrast, both groups had similar median Medical Research Council scores (evaluates muscle strength) and Barthel index scores (evaluates ability to complete activities of daily living) at discharge.
A significantly higher mean Sequential Organ Failure Assessment score was found in the intervention group compared with the control group (3.5 vs. 2.2; P = .01) at first standing,
Notably, both groups had comparable findings across several secondary outcomes: median mobilization preparation times, median mobilization cleanup times, median mobilization times, delirium presence, median delirium duration, median ICU stay duration, mean 28-day ventilator-free days, ICU mortality and hospital mortality.
When divided by sex, researchers found significant differences in days to standing between the intervention and control group in both the cohort of women and the cohort of men (P < .01). In terms of FSS-ICU between the two groups, only men showed significant differences (P = .02).
“To draw conclusive evidence for the advantages of early mobilization, further studies should accumulate supportive data,” Suzuki said in the release.
Breathing+ by Breathing Labs has passed peer review in a randomized controlled clinical trial that was recently published in SCI Q2 journal Pediatric Pulmonology. Research done by @bezmialem Full text is available in a link here: https://www.breathinglabs.com/clinical-trials/research-breathing-labs-and-nintendo-clinical-trial-is-published-in-journal-pediatric-pulmonology-sci-q2-impact-factor-3/?fbclid=IwAR2wNhSgurdbrrf3gzOOkHthgiWfXJ1x8RWvnMhkSo6fi33QPZEGzxzd6jM
BREAKING: @breathinglabs and @Nintendo clinical trial is published in journal Pediatric Pulmonology (SCI Q2, Impact Factor > 3), full text: https://breathinglabs.com/Nintendo%20&%20Breathing%20Labs%202022 #telemedicine #telehealth #mhealth
Clinical mouthpieces 10pcs packages are now available at 45€/50USD (shipping cost not included). Learn more: https://www.breathinglabs.com/latest-news/announcement-breathing-mouthpieces-for-clinical-and-professional-use-are-now-available/
BREATHING VR: Lately we are sourcing this VR headset for use in Breathing VR application. It allows easiest installation of both breathing+ headset cable, and USB charging cables, which is essential in professional use: https://www.banggood.com/VR-SHINECON-G5-VR-Glasses-3D-Virtual-Reality-Glasses-VR-Headset-For-iPhone-XS-11Pro-Mi10-p-1679808.html?rmmds=myorder&cur_warehouse=CN
Update: Each purchase of Breathing+ will now include three machine washable mouthpieces. Previous buyers will be supplied with those by their country representatives but will have to cover shipping costs. Please be patient while we arrange distribution. https://www.breathinglabs.com/latest-news/announcement-breathing-mouthpieces-for-clinical-and-professional-use-are-now-available/
Update: We moved servers + relocated all our games to our servers, please be patient while google reviews all that (showing unsafe website atm). Use duckduckgo or non-chromium browsers to reach our pages in the meantime. Everything ok + new product addons coming out in a month!
Registration and all functionalities at http://breathinglabs.com (and in our iOS and Android games) are fixed and fully working. If you find any issues -> [email protected]
We are back in stock with Breathing+, currently searching for VR supplier, and setting up mass production for toys and tens stimulation + in November we will be signing up new erasmus traineeships, research projects, bilateral, FP(eu), and asia-pacific ->[email protected]
BREAKING: Nintendo Co. Ltd (Japan) is implementing Breathing Games by @breathinglabs in FDA approved clinical trial for children with bronchiectasis: https://clinicaltrials.gov/ct2/show/NCT04038892
Notice to b2b partners: we are running late with some minor upgrade-> briefly running out of stock -> retail and b2b sale is closed until early october. To get a list of partners with stock to sell contact us at [email protected] Thanks, we'll go strong again in winter 💪